This study is investigating whether clemastine fumarate, an antihistamine, can improve the brain's white matter in older adults (age 60 and above) with depression. The goal is to see if this improvement can help antidepressant treatments work better, reduce depression symptoms, and improve memory and thinking. You may be eligible if you are over 60, have major depressive disorder with a specific symptom severity (MADRS ≥ 15), are seeking antidepressant treatment, and meet other criteria. Success will be measured by changes in side effects, depression symptoms, and white matter in the brain after 12 weeks. The current recruitment status is unclear.

Study design

This interventional study plans to enroll 80 participants. It involves two groups: one receiving standard antidepressant treatment with clemastine fumarate, and the other receiving standard antidepressant treatment with a placebo.

What's involved

Participants will receive treatment and be assessed over a period of 12 weeks. Specific visits, procedures, or tests are not detailed beyond these assessments.

Compensation

Not stated in the trial record.

Follow-up

Participants will be assessed at 12 weeks for side effects, depression symptoms, and white matter changes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.